::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

TOPICAL TRANEXAMIC ACID VERSUS HYDROQUINONE FOR PATIENTS PRESENTING WITH MELISMA

AUTHORS:

Dr. Ammara Iftikhar, Dr. Farrakh Iqbal Ghumman, Dr. Shafiq Ur Rehman

ABSTRACT:

Introduction: Epidemiologically, this condition is observed in all geographical and ethnical subgroups, but it occurs with a higher tendency in more pigmented phenotypes, such as East Asians, Middle Easterners, and Mediterranean Africans. Objectives of the study: The main objective of the study is to find the topical tranexamic acid versus hydroquinone for patients presenting with melisma. Material and methods: This descriptive study was conducted in Lahore General Hospital during June 2019 to January 2020. The data was collected from 100 patients who visited the OPD of the hospital regularly. The patients were interviewed to collect demographic and clinical data. The women were also completely examined to assess evidence of skin and physical disorders. Results: The data was collected from 100 patients. The two groups were matched for mean age (38.10 ± 6.27 vs. 39.97 ± 7.86 years, p = 0.314), history of receiving systemic drugs (especially thyroid drugs) (30.0% vs. 13.3%, p = 0.117), history of systemic disorders (13.3% vs. 6.7%, p = 0.671), and family history of melasma (50.0% vs. 46.7%, p = 0.796). With respect to the intensity and extension of disease in the two groups, the mean percentage of forehead involvement at baseline was higher in group A than in group B. Conclusion: It is concluded that topical use of TXA can significantly reduce both melanin level and MASI score. This regimen results in high patient satisfaction because of its high efficiency and low drug side effects.